Evidence map›Paper›PMID 31435712›Full record

ArticleArchives of toxicology2019

Human skin-derived ABCB5

Vanessa Hartwig, Bedair Dewidar, Tao Lin, Anne Dropmann, Christoph Ganss, Mark Andreas Kluth, Nils Tappenbeck, Lysann Tietze, Bruno Christ, Markus Frank and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Skin-Derived ABCB5International journal of molecular sciences · 2022
    Review
  5. Article
  6. Process data of allogeneic ex vivo-expanded ABCB5Stem cell research & therapy · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Vanessa HartwigSection Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Bedair DewidarSection Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Tao LinSection Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Anne DropmannSection Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Christoph GanssRHEACELL GmbH and Co. KG, 69120, Heidelberg, Germany.
Mark Andreas KluthRHEACELL GmbH and Co. KG, 69120, Heidelberg, Germany.
Nils TappenbeckRHEACELL GmbH and Co. KG, 69120, Heidelberg, Germany.
Lysann TietzeApplied Molecular Hepatology, Department of Visceral Transplantation, Thoracic und Vascular Surgery, Leipzig University, 04103, Leipzig, Germany.
Bruno ChristApplied Molecular Hepatology, Department of Visceral Transplantation, Thoracic und Vascular Surgery, Leipzig University, 04103, Leipzig, Germany.
Markus FrankDepartment of Pediatrics and Dermatology, Harvard Medical School, Boston, MA, 02115, USA.
Roger VogelmannSection Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Matthias Philip Alexander EbertSection Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Steven DooleySection Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. steven.dooley@medma.uni-heidelberg.de.ORCID 0000-0002-4840-6240
Heidelberg University · DERheacell (Germany) · DELeipzig University · DEHarvard University · USTanta University · EG

Funding

Multipotent ABCB5-positive cell therapeutics for corneal diseaseR24EY028767 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI FRANK, MARKUS H., FRANK, NATASHA Y · 2018 to 2022
$5.9M
NEI NIH HHS R24 EY028767
6 · The paper itself

Abstract

Although liver transplantation is a potential effective cure for patients with end-stage liver diseases, this strategy has several drawbacks including high cost, long waiting list, and limited availability of liver organs. Therefore, stem cell-based therapy is presented as an alternative option, which showed promising results in animal models of acute and chronic liver injuries. ABCB5

Indexed as

AnimalsATP-Binding Cassette Sub-Family B Member 4ATP Binding Cassette Transporter, Subfamily BDisease Models, AnimalHepatic Stellate CellsHumansInjections, IntravenousLiver CirrhosisLiver Function TestsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMice, Inbred BALB CMice, KnockoutABCB5 protein, mouseATP-Binding Cassette Sub-Family B Member 4ATP Binding Cassette Transporter, Subfamily BABCB5Cell therapyLiver fibrosisMdr2KOMesenchymal stromal cells

Identifiers

PMID31435712
PMCPMC13602064
OpenAlexW2969767998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.